Dent Neurologic


ACADIA RADIANT (Alzheimer’s Disease Psychosis)

In this study, researchers will evaluate ACP-204 in patients with Alzheimer’s Disease Psychosis.

Inclusion Criteria:

  •  50 years to 95  years of age
  • Meets clinical criteria for possible or probable Alzheimer’s Disease
  • Psychotic symptoms (hallucinations or delusions) for at least 2 months
  • Availability of a designated study partner/caregiver

What to Expect

Participants will receive either ACP-204 or a placebo as an oral medication. A placebo looks like the study drug but contains no real medicine.  After 6 weeks, participants may have the opportunity to enroll in an open-label extension study, where ACP-204 will be administered.

For more information click the link below or contact Tiffany Hoefler at or 716-961-9219

Subscribe To Our Newsletter

Sign up to receive email updates on announcements, new services added, company updates & more!

Want to participate in a study?

Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.

Scroll to Top